Correlation Engine 2.0
Clear Search sequence regions

  • AAV (5)
  • genes (1)
  • human (4)
  • mice (1)
  • patients (1)
  • protein human (1)
  • PRPF31 (9)
  • prpf31 protein, human (1)
  • Sizes of these terms reflect their relevance to your search.

    Mutations in PRPF31 cause autosomal dominant retinitis pigmentosa, an untreatable form of blindness. Gene therapy is a promising treatment for PRPF31-retinitis pigmentosa, however, there are currently no suitable animal models in which to develop AAV-mediated gene augmentation. Here we establish Prpf31 mutant mouse models using AAV-mediated CRISPR/Cas9 knockout, and characterize the resulting retinal degeneration phenotype. Mouse models with early-onset morphological and functional impairments like those in patients were established, providing new platforms in which to investigate pathogenetic mechanisms and develop therapeutic methods. AAV-mediated PRPF31 gene augmentation restored the retinal structure and function in a rapidly degenerating mouse model, demonstrating the first in vivo proof-of-concept for AAV-mediated gene therapy to treat PRPF31-retinitis pigmentosa. AAV-CRISPR/Cas9-PRPF31 knockout constructs also mediated efficient PRPF31 knockout in human and non-human primate retinal explants, laying a foundation for establishing non-human primate models using the method developed here. © 2022. The Author(s).


    Zhouhuan Xi, Abhishek Vats, José-Alain Sahel, Yuanyuan Chen, Leah C Byrne. Gene augmentation prevents retinal degeneration in a CRISPR/Cas9-based mouse model of PRPF31 retinitis pigmentosa. Nature communications. 2022 Dec 13;13(1):7695

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 36509783

    View Full Text